tiprankstipranks
Advertisement
Advertisement

GILD Stock Latest News

Gilead Sciences: Core HIV and Liver Franchises Drive EPS Upside and Support Buy Rating Despite Cell Therapy Headwinds
RatingsGilead Sciences: Core HIV and Liver Franchises Drive EPS Upside and Support Buy Rating Despite Cell Therapy Headwinds
6h ago
GILD
Gilead Sciences (GILD) Q1 Earnings Cheat Sheet
PremiumPre-Earnings
Gilead Sciences (GILD) Q1 Earnings Cheat Sheet
2d ago
GILD
Arcus Biosciences discontinues Star-121 study with Gilead due to futility
PremiumThe Fly
Arcus Biosciences discontinues Star-121 study with Gilead due to futility
3d ago
GILD
RCUS
Arcus Biosciences price target lowered to $47 from $49 at Leerink
PremiumThe Fly
Arcus Biosciences price target lowered to $47 from $49 at Leerink
3d ago
GILD
RCUS
The Week That Was, The Week Ahead: Macro and Markets, April 19
PremiumMarket News
The Week That Was, The Week Ahead: Macro and Markets, April 19
4d ago
T
BA
White-Collar Workers Have Been Hit Hard by Layoffs – And Things May Get Even Worse
PremiumMarket NewsWhite-Collar Workers Have Been Hit Hard by Layoffs – And Things May Get Even Worse
5d ago
BAC
JPM
Gilead receives all required regulatory approvals for Arcellx acquisition
Premium
The Fly
Gilead receives all required regulatory approvals for Arcellx acquisition
6d ago
ACLX
GILD
Trump names Erica Schwartz CDC Director
Premium
The Fly
Trump names Erica Schwartz CDC Director
7d ago
AZN
BMY
Private Markets: Slate Auto, Plata land major rounds
PremiumThe Fly
Private Markets: Slate Auto, Plata land major rounds
7d ago
ZS
ABM
Gilead: Durable HIV Franchise and Emerging Oncology Pipeline Support Buy Rating and Upside to $162 Target
PremiumRatings
Gilead: Durable HIV Franchise and Emerging Oncology Pipeline Support Buy Rating and Upside to $162 Target
8d ago
GILD
Gilead announces investment in lenacapavir by PEPFAR, The Global Fund
PremiumThe Fly
Gilead announces investment in lenacapavir by PEPFAR, The Global Fund
9d ago
GILD
Gilead put volume heavy and directionally bearish
PremiumThe Fly
Gilead put volume heavy and directionally bearish
10d ago
GILD
Gilead price target raised to $165 from $156 at Citi
PremiumThe FlyGilead price target raised to $165 from $156 at Citi
10d ago
GILD
Gilead price target raised to $175 from $171 at Morgan Stanley
Premium
The Fly
Gilead price target raised to $175 from $171 at Morgan Stanley
13d ago
GILD
MacroGenics upgraded to Buy at B. Riley after deal for Tubulus
Premium
The Fly
MacroGenics upgraded to Buy at B. Riley after deal for Tubulus
13d ago
GILD
MGNX
Tempus AI announce strategic collaboration with Gilead
PremiumThe Fly
Tempus AI announce strategic collaboration with Gilead
14d ago
TEM
GILD
Kymera Therapeutics announces Gilead option exercise to license KT-200
PremiumThe Fly
Kymera Therapeutics announces Gilead option exercise to license KT-200
14d ago
GILD
KYMR
Gilead price target raised to $155 from $152 at Truist
PremiumThe Fly
Gilead price target raised to $155 from $152 at Truist
15d ago
GILD
Gilead price target raised to $155 from $152 at Truist
PremiumThe Fly
Gilead price target raised to $155 from $152 at Truist
15d ago
GILD
Balancing Strategic Oncology Expansion and Execution Risk: Why Gilead’s Tubulis Deal Supports a Hold Rating
PremiumRatingsBalancing Strategic Oncology Expansion and Execution Risk: Why Gilead’s Tubulis Deal Supports a Hold Rating
15d ago
GILD
Gilead Sciences: Strategic Oncology Expansion and Undervalued Growth Opportunity Driving Buy Rating
Premium
Ratings
Gilead Sciences: Strategic Oncology Expansion and Undervalued Growth Opportunity Driving Buy Rating
15d ago
GILD
Gilead’s Tubulis Acquisition: Building an ADC Oncology Franchise and Enhancing Risk‑Reward for GILD Shares
Premium
Ratings
Gilead’s Tubulis Acquisition: Building an ADC Oncology Franchise and Enhancing Risk‑Reward for GILD Shares
15d ago
GILD

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >